MCID: HPT004
MIFTS: 45

Hepatic Coma

Categories: Liver diseases, Neuronal diseases

Aliases & Classifications for Hepatic Coma

MalaCards integrated aliases for Hepatic Coma:

Name: Hepatic Coma 12 56 15 74
Hepatic Encephalopathy 45 74
Hepatocerebral Intoxication 12

Classifications:



External Ids:

Disease Ontology 12 DOID:12550
MeSH 45 D006501
SNOMED-CT 69 72836002
ICD10 34 K72.91

Summaries for Hepatic Coma

MalaCards based summary : Hepatic Coma, also known as hepatic encephalopathy, is related to viral hepatitis and alcoholic liver cirrhosis. An important gene associated with Hepatic Coma is F2 (Coagulation Factor II, Thrombin), and among its related pathways/superpathways are Sterol Regulatory Element-Binding Proteins (SREBP) signalling and FOXA2 and FOXA3 transcription factor networks. The drugs Rifaximin and Metformin have been mentioned in the context of this disorder. Affiliated tissues include liver, brain and testes, and related phenotype is normal.

Related Diseases for Hepatic Coma

Diseases related to Hepatic Coma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 182)
# Related Disease Score Top Affiliating Genes
1 viral hepatitis 32.5 ALB F2 GPT
2 alcoholic liver cirrhosis 32.2 ALB F2
3 hepatitis a 31.0 ALB F2 GPT
4 liver disease 30.1 ALB F2 GPT
5 esophageal varix 29.9 ALB F2
6 liver cirrhosis 29.9 ALB F2 GPT
7 peritonitis 29.9 ALB F2
8 infantile liver failure syndrome 1 29.8 ALB F2 GPT
9 hepatitis b 29.7 ALB F2 GPT
10 schistosomiasis 29.7 ALB F2
11 hepatorenal syndrome 29.7 ALB F2
12 portal hypertension 29.5 ALB F2 GPT
13 autoimmune hepatitis 29.4 F2 GPT
14 acute liver failure 29.4 ALB F2 GPT TSPO
15 bilirubin metabolic disorder 29.3 ALB F2 GPT
16 alcoholic hepatitis 29.3 ALB F2 GPT
17 hepatitis e 29.2 ALB F2 GPT
18 hepatic encephalopathy 29.1 ALB F2 GPT TSPO
19 congenital extrahepatic portosystemic shunt 11.4
20 hepatic veno-occlusive disease 11.0
21 hepatitis 10.4
22 brain edema 10.3
23 helicobacter pylori infection 10.2
24 thrombosis 10.2
25 hepatoportal sclerosis 10.1 F2 GPT
26 hepatitis d 10.1 F2 GPT
27 nonalcoholic steatohepatitis 10.1 F2 GPT
28 status epilepticus 10.1
29 antipyrine metabolism 10.1 ALB F2
30 non-a-e hepatitis 10.1 ALB F2
31 epstein-barr virus hepatitis 10.1 ALB F2
32 diabetes mellitus 10.1
33 portal vein thrombosis 10.1
34 fournier gangrene 10.1 ALB F2
35 abdominal tuberculosis 10.1 ALB F2
36 splenic disease 10.1 ALB F2
37 ascending cholangitis 10.1 ALB F2
38 encephalopathy 10.1
39 hypersplenism 10.0 ALB F2
40 compartment syndrome 10.0 ALB F2
41 autoimmune disease of urogenital tract 10.0 ALB F2
42 hepatic vascular disease 10.0 ALB F2
43 pulmonary artery disease 10.0 ALB F2
44 hepatocellular carcinoma 10.0
45 dysfibrinogenemia 10.0 ALB F2
46 vein disease 10.0 ALB F2
47 intermittent claudication 10.0 ALB F2
48 fascioliasis 10.0 ALB GPT
49 typhoid fever 10.0 ALB F2
50 dengue hemorrhagic fever 10.0 ALB F2

Graphical network of the top 20 diseases related to Hepatic Coma:



Diseases related to Hepatic Coma

Symptoms & Phenotypes for Hepatic Coma

MGI Mouse Phenotypes related to Hepatic Coma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 normal MP:0002873 9.02 ALB DBI F2 SCN1A TSPO

Drugs & Therapeutics for Hepatic Coma

Drugs for Hepatic Coma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 296)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Rifaximin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 80621-81-4 6436173 46783403
2
Metformin Approved Phase 4 657-24-9 14219 4091
3
Lactulose Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 4618-18-2 11333
4
Midazolam Approved, Illicit Phase 4,Not Applicable 59467-70-8 4192
5
Propofol Approved, Investigational, Vet_approved Phase 4,Not Applicable 2078-54-8 4943
6
Magnesium oxide Approved Phase 4 1309-48-4 14792
7
Simvastatin Approved Phase 4,Phase 3,Phase 2 79902-63-9 54454
8
Carvedilol Approved, Investigational Phase 4,Not Applicable 72956-09-3 2585
9
Nadolol Approved Phase 4,Phase 3 42200-33-9 39147
10
Propranolol Approved, Investigational Phase 4,Phase 3,Not Applicable 525-66-6 4946
11
Entecavir Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 142217-69-4 153941
12
Norfloxacin Approved Phase 4,Phase 3 70458-96-7 4539
13
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
14
Diphenhydramine Approved, Investigational Phase 4,Not Applicable 147-24-0, 58-73-1 3100
15
Histamine Approved, Investigational Phase 4 51-45-6 774
16
Promethazine Approved, Investigational Phase 4,Not Applicable 60-87-7 4927
17
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
18
Insulin Aspart Approved Phase 4 116094-23-6 16132418
19
Midodrine Approved Phase 4,Phase 2,Phase 3,Not Applicable 133163-28-7, 42794-76-3 4195
20
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
21
Mannitol Approved, Investigational Phase 4,Not Applicable 69-65-8 453 6251
22
Terlipressin Approved, Investigational Phase 4,Not Applicable 14636-12-5 72081
23
Acetylcysteine Approved, Investigational Phase 4,Phase 3 616-91-1 12035
24
Tolvaptan Approved Phase 4,Phase 3 150683-30-0 216237
25
Tranexamic Acid Approved Phase 4 1197-18-8 5526
26
chenodeoxycholic acid Approved Phase 4,Phase 3 474-25-9 10133
27
Ornithine Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable 3184-13-2, 70-26-8 6262
28
Calcium Approved, Nutraceutical Phase 4,Not Applicable 7440-70-2 271
29
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
30
Isoleucine Approved, Investigational, Nutraceutical Phase 4 73-32-5, 443-79-8 6306
31
Tenofovir Experimental, Investigational Phase 4,Phase 3,Not Applicable 147127-20-6 464205
32 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Hypoglycemic Agents Phase 4
36 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 N-Methylaspartate Phase 4,Phase 3,Phase 2,Not Applicable
38 Excitatory Amino Acids Phase 4,Phase 3,Phase 2,Not Applicable
39 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Excitatory Amino Acid Agonists Phase 4,Phase 3,Phase 2,Not Applicable
41 Aspartic Acid Phase 4,Phase 3,Phase 2,Not Applicable
42 GABA Modulators Phase 4,Phase 1,Phase 2,Not Applicable
43 Tranquilizing Agents Phase 4,Not Applicable
44 Central Nervous System Depressants Phase 4,Phase 2,Not Applicable
45 Anti-Anxiety Agents Phase 4,Not Applicable
46 Anesthetics, General Phase 4,Not Applicable
47 Adjuvants, Anesthesia Phase 4,Not Applicable
48 Anesthetics, Intravenous Phase 4,Not Applicable
49 Hypnotics and Sedatives Phase 4,Phase 2,Not Applicable
50 Anesthetics Phase 4,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 322)
# Name Status NCT ID Phase Drugs
1 Low-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy Unknown status NCT03077217 Phase 4 Rifaximin
2 Metformin Experience on Minimal Hepatic Encephalopathy Unknown status NCT02470546 Phase 4 Metformin;Placebo
3 Primary Prophylaxis of Hepatic Encephalopathy in Patients With Cirrhosis Unknown status NCT01175538 Phase 4 Lactulose;Lactulose
4 Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis Unknown status NCT01178372 Phase 4 Lactulose;Probiotics(VSL#3)
5 Efficacy of Combined Oral L-Ornithine-L-Aspartate and Lactulose in Patients With Hepatic Encephalopathy Unknown status NCT00740142 Phase 4 L-ornithine-L-aspartate and lactulose;placebo and lactulose
6 Trial Comparing Sedation for Endoscopy With Propofol Versus Midazolam in Cirrhotics Unknown status NCT01356121 Phase 4 Propofol;Midazolam
7 Therapeutic Efficacy of Oral L-Ornithine-L-Aspartate on Minimal Encephalopathy Unknown status NCT00896831 Phase 4 L-ornithine-L-aspartate;placebo
8 Rifaximin Versus Lactulose in Renal Failure Unknown status NCT00748904 Phase 4 Rifaximin;Lactulose
9 Magnesium in Liver Cirrhosis Unknown status NCT01894867 Phase 4
10 Study About Simvastatin in Portal Hypertension in Compensated Cirrhosis Unknown status NCT01282398 Phase 4 Simvastatin;placebo
11 Assessment of Coagulation Abnormalities in Acute on Chronic Liver Failure Patients Using Thromboelastography Unknown status NCT02757170 Phase 4
12 Hemodynamic Effect of Simvastatin With Beta Blockers in Clinical Portal Hypertension Unknown status NCT01282385 Phase 4 Simvastatin;placebo
13 The Effect of Carvedilol VS Endoscopic Therapy in Primary Prophylaxis of High-risk Esophageal Gastric Variceal Bleeding Unknown status NCT02695732 Phase 4 Carvedilol
14 The Effect of Carvedilol Vs Propranolol in Cirrhotic Patients With Variceal Bleeding Unknown status NCT02385422 Phase 4 Carvedilol;Propranolol
15 The Effect of Branched-chain Amino Acid on the Improvement of Serum Albumin Level in Cirrhotic Patients With Ascites Unknown status NCT02755701 Phase 4 Branched-chain Amino Acid;Placebo
16 Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects Completed NCT01846455 Phase 4 2.0mg Buprenorphine/0.5mg Naloxone;Promethazine
17 Lactulose, L-ornithine L-aspartate, or Rifaximin Versus Placebo for Preventing Hepatic Encephalopathy in Variceal Bleeding Completed NCT02158182 Phase 4 Lactulose;L-ornithine L-aspartate;Rifaximin;Placebo
18 Post Transjugular Intrahepatic Portosystemic Shunt (Tips) Albumine Infusion to Prevent Hepatic Encephalopathy Completed NCT01559519 Phase 4 Albumin
19 Effects of Proteins in Patients With Cirrhosis and Prior Hepatic Encephalopathy Completed NCT00955500 Phase 4
20 Brain Muscle Axis During Treatment of Hepatic Encephalopathy With L-ornithine L-aspartate Completed NCT01847651 Phase 4 LOLA or placebo
21 Efficacy of L-Ornithine L-Aspartate in Acute Hepatic Encephalopathy. Completed NCT01041755 Phase 4 L-ornithine-L-aspartate;Lactose
22 Effect of Lactulose on Minimal Hepatic Encephalopathy and Health-Related Quality of Life Completed NCT00375375 Phase 4 Lactulose
23 L-ornithine L-aspartate in Overt Hepatic Encephalopathy Completed NCT01722578 Phase 4 L-ornithine L-aspartate;Placebo
24 Randomised Controlled Trial of Mechanistic Effects of Rifaximin in Cirrhosis and Chronic Hepatic Encephalopathy Completed NCT02019784 Phase 4 Rifaximin-α;Placebo Oral Tablet
25 Efficacy of Albumin for Acute Encephalopathy in Patients With Cirrhosis Completed NCT00886925 Phase 4 Albumin;Sodium chloride 0.9%
26 The Safety/Efficacy Of Rifaximin With/Without Lactulose In Subjects With A History Of Recurrent Hepatic Encephalopathy Completed NCT01842581 Phase 4 Rifaximin;Rifaximin and Lactulose
27 Branched Chain Aminoacid Supplementation in Patients With Liver Cirrhosis Completed NCT02023229 Phase 4
28 Effect of Midodrine and Albumine in the Prevention of Complications in Cirrhotic Patients Awaiting Liver Transplantation Completed NCT00839358 Phase 4 albumin;Midodrine;Placebo
29 Study on B-blockers to Prevent Decompensation of Cirrhosis With HTPortal Completed NCT01059396 Phase 4 propranolol;carvedilol;placebo
30 Ramelteon for Treatment of Insomnia in Cirrhosis Completed NCT03091738 Phase 4 Ramelteon Pill
31 Optimized Treatment and Regression of HBV-induced Compensated Liver Cirrhosis Completed NCT01943617 Phase 4 Entecavir;Thymosin-α
32 Norfloxacin Versus Ciprofloxacin for Spontaneous Bacterial Peritonitis (SBP) Prevention Completed NCT01542801 Phase 4 Norfloxacin;ciprofloxacin
33 Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy Recruiting NCT01846663 Phase 4 Placebo;Rifaximin
34 PEG (Polyethylene Glycol)Versus Lactulose For Treatment Of Overt Hepatic Encephalopathy Recruiting NCT03100513 Phase 4 Lactulose;Polyethylene Glycol
35 Albumin Infusion Effects in Mortality in Patients With Cirrhosis and Hepatic Encephalopathy Recruiting NCT02401490 Phase 4 Human albumin;Placebo
36 Efficacity and Safety of Tranexamic Acid in Cirrhotic Patients Presenting With Acute Upper Gastrointestinal Bleeding Recruiting NCT03023189 Phase 4 Tranexamic acid;Placebo
37 Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis Recruiting NCT02308111 Phase 4 Obeticholic Acid (OCA);Placebo
38 Effect of Entecavir Treatment on Regression and Disease Outcome in HBV-induced Liver Fibrosis and Cirrhosis Patients Recruiting NCT02849132 Phase 4 Entecavir
39 Rifaximin Reduces the Complications of Decompensated Cirrhosis: a Randomized Controlled Trial Recruiting NCT02190357 Phase 4 Rifaximin
40 Study of OCA Evaluating Pharmacokinetics and Safety in Patients With PBC and Hepatic Impairment Recruiting NCT03633227 Phase 4 Obeticholic Acid (OCA);Placebo
41 Sarcopenia Improves the Muscle Mass and Muscle Strength of Patients With Liver Cirrhosis-Child C Recruiting NCT03633279 Phase 4 Branched chain amino acid;Placebo
42 Efficacy of Terlipressin Therapy in Acute Variceal Haemorrhage After EVL Recruiting NCT03584087 Phase 4 Normal Saline;Terlipressin
43 Prompt Or Watchful Monitoring for Hepatitis B Virus Related Hepatocellular Carcinoma Without Elevated viRal Load Not yet recruiting NCT02308319 Phase 4 Tenofovir disoproxil fumarate
44 Beta-blockers for Oesophageal Varices Not yet recruiting NCT03776955 Phase 4 Carvedilol
45 Study of N-Acetylcysteine in Acute Liver Failure (ALF) Terminated NCT00896025 Phase 4 N-acetylcysteine
46 Quality of Life and Nutritional Improvements in Cirrhotic Patients Terminated NCT01842113 Phase 4 Rifaximin;Lactulose;Lactulose Placebo;Rifaximin Placebo
47 Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia Terminated NCT01890694 Phase 4 Tolvaptan;Placebo
48 Effect of Intrathoracic Pressure Regulation on Traumatic Brain Injury Terminated NCT01824589 Phase 4
49 Impact of an Antibiotic (Rifaximin) on Liver Scarring in HIV-Infected Patients With Liver Disease Withdrawn NCT01654939 Phase 4 Rifaximin
50 RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Controlled Trial Unknown status NCT00364689 Phase 3 Rifaximin alone, Rifaximin combined with Lactulose

Search NIH Clinical Center for Hepatic Coma

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: hepatic encephalopathy

Genetic Tests for Hepatic Coma

Anatomical Context for Hepatic Coma

MalaCards organs/tissues related to Hepatic Coma:

42
Liver, Brain, Testes, Cortex, Bone, Colon, Eye

Publications for Hepatic Coma

Articles related to Hepatic Coma:

(show top 50) (show all 2497)
# Title Authors Year
1
Neurological Complications Occurring after Liver Transplantation: Role of Risk Factors, Hepatic Encephalopathy, and Acute (on Chronic) Brain Injury. ( 30697911 )
2019
2
Prognostic significance of minimal hepatic encephalopathy in patients with liver cirrhosis in Japan: a propensity score-matching analysis. ( 30779213 )
2019
3
Adherence to Recommended Inpatient Hepatic Encephalopathy Workup. ( 30811321 )
2019
4
Specific Gut and Salivary Microbiota Patterns Are Linked With Different Cognitive Testing Strategies in Minimal Hepatic Encephalopathy. ( 30816877 )
2019
5
Hepatic encephalopathy: Lessons from preclinical studies. ( 30820267 )
2019
6
Peripheral inflammation induces neuroinflammation that alters neurotransmission and cognitive and motor function in hepatic encephalopathy: Underlying mechanisms and therapeutic implications. ( 30830722 )
2019
7
A Case of Catatonia Nearly Mistaken for Hepatic Encephalopathy. ( 30831063 )
2019
8
Development and Validation of a Prognostic Score to Predict Covert Hepatic Encephalopathy in Patients With Cirrhosis. ( 30848730 )
2019
9
Chemical exchange saturation transfer imaging in hepatic encephalopathy. ( 30856541 )
2019
10
Utility of the EncephalApp Stroop Test for Covert Hepatic Encephalopathy Screening in Chinese Cirrhotic Patients. ( 30861191 )
2019
11
Targeted puncture of left branch of intrahepatic portal vein in transjugular intrahepatic portosystemic shunt to reduce hepatic encephalopathy. ( 30862997 )
2019
12
Increasing Burden of Hepatic Encephalopathy Among Hospitalized Adults: An Analysis of the 2010-2014 National Inpatient Sample. ( 30863953 )
2019
13
Updates on the pathophysiology and therapeutic targets for hepatic encephalopathy. ( 30893082 )
2019
14
Glucuronidated bilirubin: Significantly increased in hepatic encephalopathy. ( 30905463 )
2019
15
Decreased Mean Kurtosis in the Putamen is a Diagnostic Feature of Minimal Hepatic Encephalopathy in Patients with Cirrhosis. ( 30626839 )
2019
16
The Psychomotor Vigilance Task: Role in the diagnosis of hepatic encephalopathy and relationship with driving ability. ( 30633946 )
2019
17
Early-Recurrent Overt Hepatic Encephalopathy Is Associated with Reduced Survival in Cirrhotic Patients after Transjugular Intrahepatic Portosystemic Shunt Creation. ( 30638778 )
2019
18
Proton Pump Inhibitor Use Is Associated with an Increased Frequency of New or Worsening Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt Creation. ( 30638914 )
2019
19
Modulation of sphingosine-1-phosphate receptor by FTY720 contributes in improvement of hepatic encephalopathy induced by bile duct ligation. ( 30660717 )
2019
20
Frailty Associated With Waitlist Mortality Independent of Ascites and Hepatic Encephalopathy in a Multi-Center Study. ( 30668935 )
2019
21
Lactulose Management of Minimal Hepatic Encephalopathy: A Systematic Review. ( 30688711 )
2019
22
Predicting Overt Hepatic Encephalopathy for the Population with Cirrhosis. ( 30703852 )
2019
23
Associated vitamin D deficiency is a risk factor for the complication of HCV-related liver cirrhosis including hepatic encephalopathy and spontaneous bacterial peritonitis. ( 30706253 )
2019
24
Impact of Hepatic Encephalopathy in Cirrhosis on Quality-of-Life Issues. ( 30706419 )
2019
25
Hepatic Encephalopathy: Definition, Clinical Grading and Diagnostic Principles. ( 30706420 )
2019
26
L-Ornithine L-Aspartate (LOLA) for the Treatment of Hepatic Encephalopathy in Cirrhosis: Novel Insights and Translation to the Clinic. ( 30706421 )
2019
27
Hepatic Encephalopathy in Cirrhosis: Pathology and Pathophysiology. ( 30706423 )
2019
28
Pharmacokinetic and Pharmacodynamic Properties of L-Ornithine L-Aspartate (LOLA) in Hepatic Encephalopathy. ( 30706424 )
2019
29
L-Ornithine L-Aspartate (LOLA) for Hepatic Encephalopathy in Cirrhosis: Results of Randomized Controlled Trials and Meta-Analyses. ( 30706425 )
2019
30
Functional Network-Based Statistics Reveal Abnormal Resting-State Functional Connectivity in Minimal Hepatic Encephalopathy. ( 30761070 )
2019
31
Hepatic encephalopathy and traffic accidents: Vigilance is needed! ( 30765121 )
2019
32
Special Section: Update in Hepatic Encephalopathy- Part III. ( 30765932 )
2019
33
Minimal/Covert Hepatic Encephalopathy - Impact of Comorbid Conditions. ( 30765943 )
2019
34
Prognostic Implications of Minimal/Covert Hepatic Encephalopathy: Large-scale Validation Cohort Studies. ( 30765944 )
2019
35
Hepatic Encephalopathy and Sarcopenia: Two Faces of the Same Metabolic Alteration. ( 30765945 )
2019
36
Role of Exercise in the Management of Hepatic Encephalopathy: Experience From Animal and Human Studies. ( 30765946 )
2019
37
How to Design a Multicenter Clinical Trial in Hepatic Encephalopathy. ( 30765947 )
2019
38
Bile Acids in Hepatic Encephalopathy. ( 30774268 )
2019
39
Portosystemic shunts and refractory hepatic encephalopathy: patient selection and current options. ( 30774483 )
2019
40
Establishment and evaluation of a model for predicting 3-month mortality in Chinese patients with hepatic encephalopathy. ( 30443767 )
2019
41
Protective role of chrysin on thioacetamide-induced hepatic encephalopathy in rats. ( 30500344 )
2019
42
Diagnosis of covert hepatic encephalopathy: a multi-center study testing the utility of single versus combined testing. ( 30506333 )
2019
43
Brain mitochondria as potential therapeutic targets for managing hepatic encephalopathy. ( 30578865 )
2019
44
Combination of rifaximin and lactulose improves clinical efficacy and mortality in patients with hepatic encephalopathy. ( 30587923 )
2019
45
Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). ( 30606696 )
2019
46
Acetyl-L-carnitine for patients with hepatic encephalopathy. ( 30610762 )
2019
47
Corrigendum to "Impaired brain glymphatic flow in experimental hepatic encephalopathy" [J Hepatol 69 (2019) 40-49]. ( 30616987 )
2019
48
A Randomized Controlled Trial Comparing Nitazoxanide Plus Lactulose With Lactulose Alone in Treatment of Overt Hepatic Encephalopathy. ( 29668561 )
2019
49
Living Donor Liver Transplantation in Acute Liver Failure Patients with Grade IV Encephalopathy: Is Deep Hepatic Coma Still an Absolute Contraindication? A Successful Single-Center Experience. ( 29531210 )
2018
50
Acute liver failure and hepatic encephalopathy in exertional heat stroke. ( 30061127 )
2018

Variations for Hepatic Coma

Expression for Hepatic Coma

Search GEO for disease gene expression data for Hepatic Coma.

Pathways for Hepatic Coma

Pathways related to Hepatic Coma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.02 ACACA DBI
2 10.6 ALB F2
3
Show member pathways
9.88 DBI TSPO

GO Terms for Hepatic Coma

Cellular components related to Hepatic Coma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.35 ALB DBI F2 GPT TSPO
2 endoplasmic reticulum lumen GO:0005788 8.8 ALB DBI F2

Biological processes related to Hepatic Coma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of reactive oxygen species metabolic process GO:2000379 8.62 F2 TSPO

Molecular functions related to Hepatic Coma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 pyridoxal phosphate binding GO:0030170 8.62 ALB GPT

Sources for Hepatic Coma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....